Tilray's International Cannabis Sales Soar 73%: Why Is the Market Overlooking This?

Tilray Brands (NASDAQ: TLRY), the global cannabis and consumer packaged goods company, announced a striking 73% year-over-year increase in its international cannabis sales during its fiscal third quarter of 2026. Despite this robust growth, the market's reaction to the company's achievement has been rather subdued, primarily because Tilray failed to meet profitability expectations and reported a net loss for the same period.

The company's fiscal third-quarter results revealed a record revenue of $206.7 million, surpassing analyst estimates. International cannabis sales contributed over $24 million to this figure, accounting for approximately 12% of total sales. Tilray attributes this growth to its strategy of expanding medical cannabis access in key markets such as Europe and Australia, as well as increasing production capacity in Portugal. However, despite the record revenue performance, the company significantly missed profitability targets, reporting a net loss.

Tilray is undergoing a significant metamorphosis, transitioning from a pure-play cannabis company to a "global lifestyle and consumer packaged goods company." This strategic shift involves substantial investments in its cannabis business, alongside alcoholic beverages and wellness products. The company has fortified its presence in the alcoholic beverage segment through acquisitions of craft beer brands from Anheuser-Busch and a partnership with BrewDog. Management believes these diversification efforts will create a robust platform for the distribution of cannabis-infused products in the future, particularly if cannabis is federally legalized in the United States.

The market's response to Tilray's international growth has been complex. While shares of TLRY initially surged over 8% following the earnings report, they subsequently experienced declines, and the stock continues to be viewed as a high-risk investment. Some analysts, such as Roth/MKM, upgraded the stock to "Buy," citing improvements in international operations and cost savings, maintaining a $10 price target. Nevertheless, Tilray's consistent losses since its initial public offering have led investors to approach with caution. Despite this, the positive market reaction suggests that investors are beginning to value the company for its future potential rather than its past volatility.

In a broader economic and political context, the cannabis industry is experiencing a significant structural transformation, partly driven by potential U.S. government moves towards rescheduling cannabis to Schedule III. Such a regulatory change could serve as a major catalyst for Tilray's expansion strategy in the U.S. market. Germany's Cannabis Act, which came into effect in 2024, has allowed Tilray's Aphria RX subsidiary to increase its capacity, catering to medical cannabis demand in Germany and other European nations. The company is strategically positioning its alcoholic beverage distribution network as a launchpad for cannabis-infused products once federal legalization occurs in the U.S.

Analysts and market expectations suggest that Tilray's international business is at an "inflection point." Analysts like William Kirk indicate that the company plans to increase its cannabis production capacity from the current 137 metric tons to approximately 200 metric tons. This increase in capacity is expected to significantly enhance the company's competitive position and profitability. The diversified portfolio and optimism regarding cannabis rescheduling contribute to a positive outlook for Tilray in fiscal year 2026. However, it is emphasized that the company's transformation into a CPG powerhouse may involve significant "growing pains," necessitating careful consideration.